SLC5A2 and Hypoglycemia: This was also observed in real-world studies with patients receiving dapagliflozin reporting lower rates of hypoglycaemia than other oral drugs (0.6% vs. 1.3%) [28] and decreased risk of hypoglycaemia with SGLT2 inhibitors (HR 0.76; 95% CI 0.65, 0.90; p = 0.001) [47].